Envisioning a world that is healthier and happier

For over four decades, at Transasia-Erba, our vision remains to be committed to a world that is healthier and happier. A healthier world is possible only when there is a considerable decline in the prevalence of diseases. And that is where the role of early and accurate diagnosis is of paramount importance.

Having said that, providing even regular diagnostic services to each of the 1.3 bn Indians is a huge challenge in our country that lacks basic healthcare facilities, especially at the grass-root level. We need to build a robust healthcare system with a focused approach on not only the manufacturing infrastructure, but the much needed R&D infrastructure. That is the only way we can reduce our dependency on imports.

And this is where local manufacturers, such as Transasia-Erba, have a major part to play by providing solutions that are affordable and backed by a well-knit after-sales network, to serve every part of the country. To this effect, we continue to align our efforts in three main areas – (i) to strengthen our product portfolio through world-class R&D; (ii) to scale our manufacturing base to be world-class; and (iii) to strengthen and grow our customer base in not just India but globally.

Technological advancements. India with its huge population, and an urban-rural divide, is home to a host of infectious diseases and NCDs, which demand immediate attention. The government, through its various public health programs, is working toward achieving the eradication goals for these infections. Our R&D teams in India and globally continue to collaborate to introduce the latest advancements in areas, such as molecular testing for HIV, TB, and cancer. Besides this, we are soon going to further expand our product portfolio in critical care, diabetes, clinical chemistry, coagulation, and ESR.

Notably, our global team is working on an integrated system, a nex-gen modular system for hematology, immunoassay, and clinical chemistry suitable for mid-sized labs.

Strengthening our R&D and manufacturing base. I reiterate that developing and manufacturing MedTech solutions in India is and will remain the only answer to meeting India’s need for affordable healthcare. I appreciate the government’s initiatives of setting up dedicated MedTech parks to incentivize indigenous production. Our ultra-modern facility in Vizag recently completed one year of operations and in the near future, we will be setting up a world-class Factory of the Future.

Doubling our R&D spend is a key element of our strategy. We now also have a dedicated team of R&D experts in Vizag, besides the ones in Mumbai, France, UK, Austria, Czech Republic, and USA that is driving innovation to strengthen our R&D pipeline and accelerate long-term growth.

Expanding our reach. Our sales and technical and applica­tion support teams are our biggest strength that augment our quality product portfolio. In fact, we are proud to have the largest team of over 800 sales and service experts in the Indian IVD Industry that caters through 25 zonal offices and 130+ service locations in India (the highest in the Indian IVD Industry). We are also strengthening our distributor network to cater to every part of the country. Our quality, affordability, and accessibility have made us the preferred choice for several large public procurement projects for the state and the central government.

On the global front too, we are looking at foraying into new overseas market, especially the emerging countries. Our Made in India products too are gaining global recognition, as we continue to cater through the large export orders. We are already exporting our diagnostic equipment to over 100 countries. We look to expand this number to cover 130 countries.

Collaboration. We recognize that regular exchange of knowledge and technical know-how between our teams in India and globally helps us in our mission of meeting the needs of doctors and patients for reliable, affordable, and innovative medical diagnostic solutions.

Marketing strategy. The pandemic has further opened up vistas of opportunities for digitization. We are actively working on further strengthening our online presence.

Outlook. In addition to launching of new and advanced diagnostic systems in CLIA, molecular, high-end hematology, artificial intelligence, LIS, etc., we will soon be launching a very innovative and affordable Total Lab Automation solution for mid- and large-size laboratories. All these will make Transasia-Erba among the top five companies globally to have total solutions in laboratory diagnostics.

2022 will be a landmark year for Transasia-Erba, in which it will be launching many hi-tech solutions that will enhance clinical outcomes for a healthy and happy world.